Llwytho...
Product review: avelumab, an anti-PD-L1 antibody
Although immunotherapies have been employed for many decades, immune checkpoint inhibitors have only recently entered the oncologic landscape. Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppress...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Hum Vaccin Immunother |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Taylor & Francis
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6605872/ https://ncbi.nlm.nih.gov/pubmed/30481100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1551671 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|